96 results
424B5
RYTM
Rhythm Pharmaceuticals Inc.
16 Oct 19
Prospectus supplement for primary offering
5:25pm
Policy
S-21
Dilution
S-22
Material United States Federal Income and Estate Tax Consequences to Non-U.S. Holders of our Common Stock
S-23
Underwriters
S … could result in further dilution to our shareholders.
S-22
MATERIAL UNITED STATES FEDERAL INCOME AND ESTATE TAX CONSEQUENCES TO
NON-U.S. HOLDERS
424B5
RYTM
Rhythm Pharmaceuticals Inc.
5 Feb 21
Prospectus supplement for primary offering
5:26pm
. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
S-16
UNDERWRITING
S-20
LEGAL MATTERS
S-28
EXPERTS
S-28
WHERE YOU CAN FIND MORE INFORMATION
S-29 …
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
The following discussion is a summary of the material U.S. federal income tax
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
9 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
4:14pm
deferred tax assets, and the fair value of the Series A Investor Instrument. See Note 4.
Rhythm Pharmaceuticals, Inc.
Notes to Consolidated Financial … corporation for federal income tax purposes. Income taxes for the Company are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740
424B5
4xz2q3
14 Sep 22
Prospectus supplement for primary offering
4:05pm
424B5
00e9lb5vn 2k134q9h
15 Sep 22
Prospectus supplement for primary offering
4:00pm
424B5
edbc464449zv1wql
15 Oct 19
Prospectus supplement for primary offering
4:51pm
424B5
wf555m7dpc2su gl27kd
3 Feb 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-2.1
cjuktmv
5 Jan 21
Entry into a Material Definitive Agreement
4:49pm
10-Q
EX-10.2
c769kb27 cr4y
14 Nov 17
Quarterly report
12:00am